Milestone Scientific Announces Advertising of Arjan Haverhals to CEO
6 min readGet within Wall Avenue with StreetInsider Premium. Claim your 1-week free demo right here.
Finance veteran Scott Kahn appointed CFO
Leonard Osser elected Vice Chairman of the Board of Directors
ROSELAND, N.J., Could 13, 2021 (Globe NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug shipping and delivery devices that offer painless and specific injections, nowadays introduced that in connection with the Company’s earlier disclosed succession program: Leonard Osser declared his intention to resign as Interim Main Govt Officer the Board of Administrators has promoted Jan Adriaan (Arjan) Haverhals, President of the Organization, to also provide as Chief Govt Officer of Milestone Scientific and Leonard Osser has been elected Vice Chairman of the Board of Directors of the Enterprise – every powerful May 19, 2021. The Company is also pleased to announce that it has appointed Scott Kahn as Main Money Officer, powerful May possibly 24, 2021. Mr. Kahn will be successful Joseph D’Agostino who retired from Milestone Scientific previous month.
Leonard Osser, Interim CEO of Milestone Scientific, stated, “I am pretty pleased to announce Arjan’s advertising to CEO of Milestone Scientific. It is well deserved as Arjan has been instrumental in implementing profitable product sales and advertising and marketing things to do all-around the dental instrument and accelerating the commercialization of CompuFlo® and CathCheck™. Arjan’s sturdy management will be invaluable as we perform toward our target of developing our technologies as regular of treatment in epidural techniques during labor and shipping and delivery, around the planet. Moreover, we are pleased to welcome Scott Kahn to the administration workforce. Scott provides more than 40 several years of leadership with a proven keep track of record in company and finance and functions. His deep experience and sturdy observe report as a CFO of many pharmaceutical and professional medical product businesses will be crucial as we improve our corporation and develop our international footprint. I search ahead to playing an active job in the development and success of the Enterprise going ahead.”
“The Corporation and Board of Administrators would like to convey our sincere gratitude to Leonard Osser for his considerable contributions and outstanding management he delivered Milestone more than the decades,” stated Leslie Bernhard, Chairman of the Board of Milestone Scientific. “Len has executed on a centered vision of advancing and providing Milestone’s computerized drug supply devices to marketplace and we glimpse ahead to continuing to profit from his thoughtful counsel and energetic involvement in the Business as the Vice Chairman of the Board. In addition, Leonard Osser will carry on as Handling Director of China Operations. We have been making ready this transition for some time and search ahead to Arjan’s participation in his new role as CEO as we prepare for the following stage of our development.”
About Arjan Haverhals
Mr. Haverhals has served as Milestone Scientific’s President considering that September 2020 and as President and Chief Government Officer of Milestone Scientific’s Dental Division, Wand Dental Inc., given that June 2020. He delivers extra than 30 decades of gross sales, promoting, solution enhancement, and international enlargement experience inside the clinical product, pharmaceutical, and other industries. Prior to joining the Business, Mr. Haverhals was Senior Vice President of Income at Xcentric Mildew & Engineering, where by he was instrumental in raising gross sales productiveness and effectiveness for the firm’s prototype injection molding services, which incorporated major healthcare company clients. Earlier, at Straumann, LLC, a world-wide chief in production medical and dental devices with in excess of $1 billion in product sales, he held a collection of senior revenue and promoting roles which include Vice President of buyer marketing & schooling, exactly where he oversaw all merchandise franchises and led the start of more than 30 items in the North American industry, ensuing in double-digit expansion. He also served as Senior Vice President for the Nordic Region at Straumann AB, Senior Vice President of World wide Revenue Electronic Answers, which integrated oversight of the strategic acquisition of Etkon and served as Vice President of the Prosthetics Business Unit, the place he launched a new implant and prosthetics products line in just a new market place section. He also served as Vice President of World-wide Advertising & Product sales at Elkem AS, one of Norway’s largest industrial companies. Previously, Mr. Haverhals served as Executive Vice President of Promoting & Product sales at Cresco Ti Techniques Sàrl, a worldwide dental implant business, where he was responsible for turning close to and controlling global sales, promoting, and international company, wherever he achieved around 100{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} return on expense for shareholders. Mr. Haverhals retains an MS in Pharmacy from the College of Leyden in the Netherlands.
About Scott Kahn
Scott Kahn is a seasoned financial leader with over 4 decades of knowledge in numerous organizations from Fortune 500 businesses to get started-ups. Prior to joining Milestone Scientific, Mr. Kahn served as CFO and Vice President at Diopsys since July 2006 in which he was responsible for all accounting, finance, human resources and trader relations. Prior to becoming a member of Diopsys, Mr. Kahn served as CFO at Diamond Chemical Co., Inc., a privately held chemical manufacturer. Prior to turning out to be CFO at Diamond Chemical Co. Inc., Mr. Kahn was a Company Controller of Pharmaceutical Formulations, Inc., a publicly traded pharmaceutical manufacturer. Earlier, Mr. Kahn held numerous finance, method and operational management roles. Mr. Kahn gained a B.A. in Accounting from Franklin and Marshall University and an M.B.A. in Worldwide Organization from Rutgers College. He is a Qualified Community Accountant licensed in the Point out of New York.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technologies exploration and progress enterprise that patents, types and develops impressive diagnostic and therapeutic injection technologies and devices for medical, dental, beauty and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, economical, and nearly painless. Milestone’s proprietary DPS Dynamic Strain Sensing technology® is our engineering system that developments the enhancement of upcoming-era devices, regulating stream charge and monitoring tension from the suggestion of the needle, by platform extensions for community anesthesia for subcutaneous drug shipping and delivery, with certain apps for beauty botulinum toxin injections, epidural place identification in regional anesthesia procedures and intra-articular joint injections. For extra information you should go to our web-site: www.milestonescientific.com.
Harmless Harbor Statement
This press launch includes ahead-looking statements concerning the timing and money impression of Milestone’s capability to employ its company approach, envisioned revenues, timing of regulatory approvals and future accomplishment. These statements require a number of hazards and uncertainties and are dependent on assumptions involving judgments with regard to foreseeable future economi
c, aggressive and current market ailments, potential small business selections and regulatory developments, all of which are difficult or unattainable to forecast precisely and numerous of which are over and above Milestone’s management. Some of the critical factors that could induce actual results to differ materially from individuals indicated by the forward-looking statements are common economic problems, failure to achieve envisioned revenue expansion, adjustments in our working bills, adverse patent rulings, Food and drug administration or authorized developments, aggressive pressures, modifications in client and marketplace necessities and requirements, and the risk elements detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Fee, including with no limitation, Milestone’s Once-a-year Report for the 12 months finished December 31, 2020. The forward-looking statements in this push launch are dependent on management’s realistic belief as of the day hereof. Milestone undertakes no obligation to revise or update publicly any ahead-looking statements for any rationale.
Get in touch with:David Waldman or Natalya RudmanCrescendo Communications, LLCEmail: [email protected]Tel: 212-671-1020
Resource: Milestone Scientific, Inc.
